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A greater understanding of non–small-cell lung cancer at a molecular 
level has led to the identification of an increasing number of driver 
mutations. Extensive research of the KRAS gene as well as specific 
mutations has established its role in tumorigenesis. Nevertheless, 
the role of KRAS oncogene in non–small-cell lung cancer remains 
unclear. Recent studies indicated that mutant KRAS could be predic-
tive of lack of response to chemotherapy, but large pooled analysis 
failed to confirm this result. The predictive value of KRAS muta-
tion and EGFR-TKI treatment is more ambiguous with some recent 
 evidence suggesting that it may be a negative predictive biomarker. 
This review provides an overview of RAS biology, assesses the utility 
of KRAS as a prognostic marker, and evaluates its role as a predictive 
marker for response to chemotherapy and EGFR-TKIs. In addition, 
we review some current studies that are targeting the KRAS pathway.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor, KRAS, Mutations, Erlotinib, Gefitinib, Cetuximab.
(J Thorac Oncol. 2013;8: 530-542)
Non–small-cell lung cancer (NSCLC) accounts for more than 85% of all lung cancer cases, with the main histologic 
subtypes consisting of adenocarcinoma and squamous cell 
 carcinoma.1–4 Efforts to improve on the 16% overall  survival 
(OS) rate are focused on early detection, as well as identifying 
key signaling pathways involved in tumor initiation, growth, 
and metastasis and the development of  targeted therapies 
directed at abnormalities in these regulatory  networks. The 
ultimate goal is to identify predictive markers for treatment 
efficacy in NSCLC, thereby allowing individualized patient 
treatment, maximizing benefit, and avoiding unnecessary 
 toxicity and expenditure for those unlikely to respond.
The strongest clinical prognostic factors in NSCLC 
include stage, sex, age, and performance status.5–7 Recently, 
alterations in key molecular pathways in subgroups of patients 
with NSCLC have been shown to have both prognostic and 
predictive significance.8–10 Furthermore, the availability of 
multiplex assays that can detect many mutations in tumor tis-
sue has resulted in oncogenic driver mutations being identi-
fied in up to 60% of adenocarcinomas.11,12 Mutation in the 
KRAS proto-oncogene, one of the most common mutations 
in NSCLC, is found in approximately 30% of adenocarcino-
mas and less commonly in squamous NSCLC (approximately 
5%).13,14 KRAS also displays variation in frequency according 
to patient ethnicity (more common in white population than 
in Asians) and is more common in current or former smokers 
compared with life time nonsmokers14,15 Most KRAS muta-
tions in NSCLC are single amino acid substitutions in codon 
12 and to a lesser extent codons 13 and 61.15–18 Never smok-
ers are more likely to have transition mutations (substituting 
purine for purine or pyrimidine for pyrimidine e.g., G→A), 
whereas current or former smokers most commonly have 
transversion mutations (substituting a pyrimidine for a purine 
or purine for a pyrimidine e.g., G→T or G→C).15,19–21
In this review, we summarize RAS biology, assess the 
utility of KRAS as a prognostic marker, and evaluate its role as 
a predictive marker for response to chemotherapy and EGFR 
inhibitors. In addition, we review current studies targeting the 
KRAS pathway.
LITERATURE SEARCH
PubMed was searched using the following key words: 
non-small cell lung cancer, KRAS, epidermal growth factor 
receptor (EGFR), EGFR inhibitor, erlotinib, gefitinib, 
chemotherapy, cetuximab, and mutation. The proceedings of 
the American Society of Clinical Oncology annual meeting 
and the World Conferences on Lung Cancer were searched 
from 2002 to 2012 using the same keywords. Search results 
were limited to articles in English. We searched www.
ClinicalTrials.gov to identify clinical trials with KRAS 
analysis.
Biology
The identification of the RAS family of genes, a protein 
subfamily of small GTPases, dates back over 40 years to the dis-
covery that these transforming oncogenes were responsible for 
the cancer-causing activities of the Harvey (HRAS) and Kirsten 
(KRAS) murine sarcoma viruses.22–24 Three RAS genes encode 
four highly related protein isoforms (HRAS, KRAS [splice 
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variants K4A- and K4B-], and NRAS) with common intrinsic 
GTPase activity.25–27 KRAS is mutated in approximately 22% 
of all tumors.18 RAS proteins function as binary switches of 
guanosine diphosphate (GDP)/guanosine triphosphate (GTP) 
(Fig. 1). In the resting cell, RAS is bound to GDP and is inac-
tive.14 Extracellular stimuli such as EGF result in the activated 
GTP-bound form of RAS.14 RAS proteins are activated by 
guanosine nucleotide exchange factors that exchange GDP for 
GTP. Activated GTP-RAS conveys EGFR signal activation to 
multiple downstream pathways that regulate cellular functions 
including proliferation, growth, motility, and survival. KRAS 
binds to GTP and possesses an intrinsic activity that cleaves 
the terminal phosphate of the nucleotide converting it to its 
inactive GDP state. This exchange reaction is catalyzed by 
GTPase-activating proteins. Activating RAS mutations prevent 
hydrolysis and therefore RAS is permanently in an “on” state, 
resulting in persistent activation of downstream effectors.25–27
RAS family proteins have 85% homology including 
the guanine nucleotide- and effector-binding core; however, 
the carboxy-terminal sequences of the various RAS proteins 
differ.25–27 The precursors of RAS proteins contain a carboxy-
terminal – CAAX motif. RAS proteins are isoprenylated in the 
cytoplasm by protein farnesyltransferase.25 This addition of a 
15-carbon chain makes RAS protein hydrophobic and facilitates 
incorporation of the protein into the inner cell membrane.25 
After this, –AA residues are removed by an endoprotease 
called RAS-converting enzyme-1 and then carboxy methylated 
on their farnesylated cysteine residue by an enzyme called 
isoprenylcysteine carboxyl methyltransferase-1.26 The final post-
translational modification of K-ras4A involves palmitoylation 
of cysteine residues upstream from the CAAX motif which aids 
in membrane anchorage.25–28 This palmitoylation reaction does 
not occur with K-rasB protein.27 When ligands such as EGF 
bind to the receptor tyrosine kinases (RTK), the RTK dimerizes 
and activates the intracellular tyrosine kinase. This leads to 
the protein growth factor receptor-bound protein 2 (GRB2) 
binding to the RTK via the sequence homology 2 (SH2) domain 
and recruitment of the RAS guanine nucleotide exchange 
factor son of sevenless homologue-1 (SOS1) and SOS2.25 
Binding of SOS to RAS leads to a conformational change of 
RAS and dissociation of GDP. This in turn allows binding of 
GTP to RAS and activation. The result of this is activation 
of several downstream effectors such as phosphoinositide-3 
kinase (PI3K), serine-threonine kinase raf-1, RAS association 
domain-containing family, T-cell lymphoma and invasion 
and metastasis, phospholipase which initiate several signal-
transduction cascades.28–30 The MAP pathway is involved in 
fundamental cellular processes such as growth, differentiation, 
proliferation, migration, and apoptosis. PI3K plays vital roles in 
regulating cell proliferation and growth.30,31
Prognostic Value of KRAS
The reported incidence of KRAS mutation in NSCLC 
ranges from 6 to 46% (Table 1). KRAS mutations were described 
as a negative prognostic marker in lung adenocarcinoma more 
than 20 years ago,41 and since then, the prognostic signifi-
cance of KRAS has been investigated extensively in NSCLC. 
The results, however, have been inconsistent (Table 1), with 
 considerable heterogeneity among studies including differing 
end points and patient populations studied.
FIGURE 1. RAS signaling pathway.
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Randomized controlled trials of adjuvant therapy have 
provided large cohorts for assessment of KRAS as a prognostic 
marker. Eastern Cooperative Oncology Group (ECOG) E4592 
was a laboratory correlative study of E3590, a randomized 
trial of adjuvant thoracic radiation ± four cycles of cisplatin/
etoposide in patients with resected stage II-IIIA NSCLC.37 Of 
184 tumors assessable for KRAS, 4.8% of squamous carci-
nomas had mutations, compared with 33% of nonsquamous 
histology (p < 0.05). Multivariate analysis revealed only age 
(p = 0.032) and tumor stage (p = 0.004) to be significant prog-
nostic factors, although there was a trend for KRAS genotype 
(p = 0.066).37 The median OS of patients with KRAS mutation 
was 30 versus 42 months for wild type (p = 0.38).37
In JBR.10, a North American intergroup trial, 482 
patients with resected stage IB-II NSCLC, stratified by KRAS, 
were randomized to receive four cycles of adjuvant cisplatin/
vinorelbine or observation alone. Mutations in RAS genes 
were identified in 26% patients. In the observation arm, RAS 
mutation was not prognostic for survival (p = 0.40).38,42
The International Agency for Research on Cancer 
(IACR) assessed the prognostic value of KRAS in the 
European Early Lung Cancer (EUELC) cohort of 762 patients 
with resected NSCLC. KRAS mutations were detected in 
18.5% available samples (adenocarcinoma 41/134 [30.6%] 
and squamous 5/115 [4.3%]). KRAS was not prognostic for 
progression-free survival (PFS) (p = 0.26).34
In the International Adjuvant Lung Cancer Trial (IALT), 
1867 patients were randomized to receive postoperative 
cisplatin-based adjuvant chemotherapy (ACT) or observation. 
KRAS mutation was detected in 14% of assessable samples. 
There was a borderline prognostic effect on disease-free sur-
vival (DFS) (p = 0.03) but not OS (p = 0.31). However, in 
the small nonsquamous/nonadenocarcinoma subset, there 
was a significant negative prognostic effect for OS and DFS 
(p = 0.04 and p = 0.006, respectively).36
In Cancer and Leukemia Group B-9633 (CALGB-
9633), a phase III trial that randomized patients with stage 
IB NSCLC to observation or four cycles of carboplatin/
paclitaxel, KRAS mutations were detected in 27% of available 
samples. There was no prognostic effect of KRAS mutation (p 
= 0.747).32
In view of the variable results from individual studies, 
a large meta-analysis of 28 studies was performed to assess 
the prognostic significance of the RAS proto-oncogene on 
survival in lung cancer.39 In this meta-analysis, the pres-
ence of KRAS mutations was a negative prognostic factor 
for OS (p = 0.01). In adenocarcinoma, KRAS was prognostic 
for OS (hazard ratio [HR]: 1.52; confidence interval [CI]: 
1.30–1.78; p = 0.02) but not in squamous histology (HR: 
1.49; CI: 0.88–2.52; p = 0.48).39 KRAS mutation was a sig-
nificant prognostic marker when polymerase chain reaction 
sequencing (HR: 1.40; 95% CI: 1.18–1.65; p = 0.03) was 
used as the detection method.
The Lung Adjuvant Cisplatin Evaluation-Bio (LACE-
Bio) group conducted a pooled analysis of KRAS status in 
1721 patients who participated in four randomized trials of 
TABLE 1.  Select Studies of KRAS as a Prognostic Marker in NSCLC
Author/trial (year)a
No. of patients in trial/ 
no. of patients with 
KRAS results
KRAS status (%)
PFSb, HR (CI) PFS, p value OSb, HR (CI) OS, p valueMutation Wild-type
Capelletti et al. (2010)32 344/258 71 (27%) 187 (73%) NR NR 1.1 0.747
CALGB-9633
Grossi et al.(2003)33 269/249 47 (19%) 202 (81%) NR NR 1.46 (0.96–2.22) 0.078
Scoccianti et al. (2012)34 762/249 46 (18%) 203 (81%) 1.30 (0.82–2.06) 0.26 NR NR
Kern et al. (1994)35 46/44 16 (36%) 28 (64%) NR NR 1.7 (0.8–3.5) 0.16
Ma et al. (2008)36 1867/718 98 (14%) 620 (86%) NR 0.03 NR 0.31
IALT
Schiller et al. (2001)37 217/184 44 (24%) 140 (76%) NR NR NR 0.68 (radiotherapy arm)
ECOG 4592
Tsao et al. (2007)38 482/450 117 (26%) 333 (74%) NR NR 1.23 (0.76–1.97) 0.40
JBR.10
Pooled analyses and 
meta-analyses
Mascaux et al. (2005)39 5216/3779 695 (18%) 3084 (82%) NR NR 1.30 (1.20–1.49) 0.01
Tsao et al. (2010)40 3533/1536 303 (20%) 1233 (80%) 1.15 (0.96–1.39) 0.13 1.18 (0.97–1.44) 0.09
LACE-Bio
Tsao et al. (2010)40 206/602 206 (34%) 396 (66%) NR NR 1.01 (0.79–1.3) 0.93
LACE-Bio
Adenocarcinoma
Hazard ratios above 1.0 indicate a poorer outcome.
aStudies using samples from a randomized clinical trial; other reports represent case series.
bAll hazard ratios compare survival of patients with KRAS mutant tumors to those with KRAS wild-type tumors as the control.
CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; NR, not reported; OS, overall survival; PFS, progression-free survival.
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ACT or observation (ANITA,44 IALT, JBR.10, CALBG-
9633) (Table 1). Analyses were performed in a blinded 
manner in three laboratories by restriction fragment length 
 polymorphism, allelic specific oligonucleotide hybridiza-
tion, or allelic refractory mutation system analysis and mass 
 spectrometry; these methods have been reported to be more 
sensitive than direct sequencing. Among 1532 samples avail-
able with KRAS results, mutations were detected in 19.7% 
(adenocarcinoma 206/602 [34%], squamous 44/705 [6%], 
and other histology 53/229 [23%]). Mutations also were 
more frequent in women, younger patients, and early stage, 
but in multivariate analysis, only age (p = 0.04) and histology 
(p < 0.0001) remained significant. Mutation status was not 
prognostic for OS (p = 0.09) or DFS (p = 0.13), with no sig-
nificant heterogeneity among trials (p = 0.60), nor was KRAS 
prognostic in the adenocarcinoma subgroup (p = 0.93).40 
There was no difference in prognosis for OS for codon 
12 (HR: 1.04; CI: 0.77–1.40) or codon 13 (HR: 1.01; CI: 
0.47–2.17)  mutations in the observation arm.45
Predictive Value of KRAS Mutation 
for Chemotherapy
Several studies have assessed the predictive value of 
KRAS mutations in patients with NSCLC treated with chemo-
therapy (Table 2). In a study by Rosell et al.,46 patients with 
stage IIIA NSCLC were randomized to undergo immediate 
surgery or to receive three cycles of preoperative chemother-
apy (mitomycin/ifosfamide/cisplatin) followed by surgery. 
There was no significant survival difference in the surgical 
arm when broken down by KRAS status, but because of small 
numbers, no meaningful conclusions can be drawn.
Rodenhuis et al. assessed KRAS in 83 patients with 
advanced adenocarcinoma treated with ifosfamide/carbopla-
tin/etoposide; 26% had mutations.47 There was no significant 
difference in response rate, PFS, or OS between KRAS mutant 
and wild-type patients (p = 0.486; p = 0.22, and p = 0.29, 
respectively).
The phase III Tarceva Responses in Conjunction with 
Paclitaxel and Carboplatin (TRIBUTE) trial in advanced 
NSCLC compared first-line carboplatin/paclitaxel plus erlo-
tinib or placebo.16 KRAS mutations were present in 21% of 
samples tested. Response rates in the chemotherapy-alone 
arm were 26 and 23% for patients with wild-type and mutated 
KRAS, respectively, with no significant survival difference 
in patients with KRAS mutant or wild-type tumors (median 
survival: 13.5 and 11.3 months, respectively). However, as all 
patients received chemotherapy in this study, no significant 
interaction could be detected.16
In NCIC CTG JBR.10, RAS was analyzed prospectively 
and patients stratified by RAS status.38 Survival was prolonged 
with ACT in patients with wild-type RAS (p = 0.03), whereas 
there was no significant benefit from chemotherapy in patients 
with RAS mutant tumors (p = 0.87); the interaction was not 
significant (p = 0.29).42
The LACE-Bio pooled analysis revealed no signifi-
cant effect of KRAS mutation on benefit from ACT with 
respect to OS or DFS,40 even in adenocarcinoma (interaction 
p = 0.99). Analysis by KRAS subtype suggests no benefit 
for OS in patients with codon 12 (HR: 0.95; CI: 0.67–1.35; 
p = 0.77).45 Patients with codon 13 mutations had significantly 
poorer outcomes with chemotherapy than observation alone 
(HR: 5.78; CI: 2.06–16.2; p < 0.001). However, with only 24 
patients in this subgroup, validation is required.
Predictive Value of KRAS Mutation 
for EGFR Inhibitors
The value of KRAS mutation testing has been estab-
lished in metastatic colorectal cancer where EGFR mono-
clonal antibodies have shown greater efficacy in patients 
with KRAS wild-type tumors.51,52 KRAS is downstream from 
EGFR, and it was hypothesized, therefore, that KRAS muta-
tion could constitutively activate its downstream effectors 
independently of upstream tyrosine kinase receptor activation, 
in particular EGFR, and therefore, could cause resistance to 
EGFR inhibitors. Multiple NSCLC trials involving EGFR-
TKIs have assessed KRAS as a predictive marker for response 
to treatment (Table 3).
In TRIBUTE, patients with KRAS mutant tumors who 
were treated with chemotherapy plus erlotinib had shorter 
median TTP (3.4 months; 95% CI: 1.5–6.3 months) than those 
treated with chemotherapy alone (6 months; 95% CI: 4.9–7.1 
months; p = 0.03).16 OS was also significantly shorter in the 
KRAS mutant subgroup treated with erlotinib plus chemother-
apy (HR: 4.4 months; 95% CI: 3.4–12.9 months) than those 
with KRAS mutation reveiving chemotherapy alone (13.5 
months; 95% CI: 11.1–15.9 months; p = 0.019).17
Two phase III trials comparing single agent EGFR TKI 
therapy to best supportive care assessed KRAS as a predic-
tive marker. The Iressa Survival Evaluation in Lung Cancer 
(ISEL) that compared gefitinib with best supportive care in 
advanced NSCLC, analyzed 152 of 1692 tumor samples, 
with KRAS mutation detected in 7.9% (n = 12). Because of 
small numbers, no meaningful conclusion was drawn from 
this study.54 In the NCIC CTG BR.21 trial of erlotinib versus 
placebo in advanced NSCLC, KRAS mutations were found 
in 15% of response-assessable patients in the erlotinib arm.16 
Response rates were 10% for those with wild-type KRAS and 
5% for those with KRAS mutant tumors (p = 0.69). There was 
no significant difference in survival benefit from erlotinib 
based on KRAS status (interaction p = 0.09) or multivariable 
analysis (p = 0.13), despite an apparent trend in univariate 
analyses (KRAS mutant HR [erlotinib versus placebo] 1.67; 
95% CI: 0.62–4.50; p = 0.31; KRAS wild-type HR: 0.69; 95% 
CI: 0.49–0.97; p = 0.03).17
Two trials assessed the role of maintenance EGFR TKIs 
in advanced NSCLC, “A randomized, double-blind, placebo-
controlled, phase IIIb trial comparing bevacizumab therapy 
with or without erlotinib after completion of chemother-
apy with bevacizumab for the first-line treatment of locally 
advanced, recurrent, or metastatic non–small-cell lung can-
cer,” (ATLAS) trial randomized responding/stable patients 
after first-line chemotherapy plus bevacizumab to continue 
bevacizumab plus erlotinib or bevacizumab/placebo; the 
median PFS improvement was 1 month.70 In 93 patients with 
KRAS mutant tumors, there was no PFS benefit with the addi-
tion of erlotinib (HR: 0.93; 95% CI: 0.55–1.56; p = 0.7697), 
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TABLE 2.  Select Studies of KRAS as a Predictive Marker for Chemotherapy in NSCLC
Author/Study (year)
Trial design KRAS Status(%) ORR (%) PFS, HR (CI) OS, HR (CI)
No. of patients in 
trial/ No. of patients 
with KRAS results WT Mut WT Mut WT Mut WT Mut
Rosell et al. (1995)46 Induction 
chemotherapy and 
surgery vs surgery 
in Stage IIIA
31 (70%) 13 (30%) NR 1/3 33% NR NR NR NR
60/44
Rodenhuis et al. (1997)47 All patients received 
chemotherapy for 
advanced NSCLC
46 (74%) 16 (26%) 12/46 (26%) 3/16 (19%) Median 5 mo Median 4 mo Median 9 mo Median 8 mo
83/62 p = 0.486 p = 0.22 p = 0.29
Schiller et al (2001)37 Postoperative RT 
± chemotherapy 
in patients with 
resected stage II 
and IIIA NSCLC
140 (76%) 44 (24%) NR NR NR NR Median 42 mo  
(CI: 34–64)
Median 30 mo  
(CI: 34–64)
E3590/4592 217/184 NS p = 0.38
RT/Chemo arm: 
106/90
70 (78%) 20 (22%) NR NR NR NR Median 41.8 mo Median 24.7 mo
p = 0.09
Eberhard et al. (2005)16 Patients with IIIB/
IV NSCLC 
randomized to CP 
± erlotinib
209 (79%) 55 (21%) 27/103 (26%) 7/30 (23%) TTP 5.4 mo  
(CI: 4.4–6.1)
TTP 6.0 mo  
(CI: 4.9–7.1)
11.3 mo (95% 
lower confidence 
limit: 9.1)
13.5 mo  
(CI: 11.1–15.9)
TRIBUTE CP alone arm
540/264
Broermann et al. (2001)48 Neoadjuvant 
chemoradiotherapy 
for all patients
15 (54%) 13 (46%) 12/15 (80%) 10/13 (77%) 21 mo 9 mo NR NR
40/28
p = 0.003 p = 0.07
Tsao et al. (2007)38 Adjuvant 
chemotherapy vs. 
observation
333 (74%) 117 (26%) NR NR NR NR 0.69 (0.49–0.97) 
p = 0.03
0.95 (0.53–1.7)  
p = 0.87
JBR.10 482/450 NR Interaction p = 0.29
Tsao et al. (2010)40 Adjuvant 
chemotherapy vs 
observation
1233 (80.3%) 303 (19.7%) NR NR 0.86 (0.74–0.99) 
p = 0.045
0.92 (0.67–1.24) 
p = 0.57
0.89 (0.76–1.06) 
p = 0.20
1.02 (0.73–1.41) 
p = 0.91
LACE-Bio 3533/1536 Interaction p = 0.70 Interaction p = 0.50
Tsao et al. (2010)40 Adjuvant 
chemotherapy vs 
observation
396 (65.8%) 206 (34.2%) NR NR NR NR 0.87 (0.65–1.16) 0.87 (0.58–1.3)
LACE-Bio 602/602 NR Interaction p = 0.99
Adenocarcinoma
Brady et al. (2012)49 Consecutive patients 
diagnosed with IV 
NSCLC treated 
with platinum-
based combination 
chemotherapy 
(platinum and 
pemetrexed in 31 
patients)
34 (69.4%) 15 (30.6%) NR NR NR NR 19 mo 15.6 mo
106/49
HR: 1.24 (95% CI: 0.57–2.67)
Levy et al. (2012)50 Retrospective review 
of patients treated 
with carboplatin 
or cisplatin and 
pemetrexed ± 
bevacizumab
19 (54.3%) 16 (45.7%) 7/19 (36%) 9/16 (56%) 5.7 mo 10.3 mo NR
35/35
p = 0.3 p = 0.03
CI, confidence interval; CP, paclitaxel/carboplatin; HR, hazard ratio; mo, months; Mut, mutation; NR, not reported; ORR, objective response rate; OS, overall survival; PFS, 
progression-free survival; TTP, time to progression; WT, wild type.
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TABLE 3.  Select Studies of KRAS as a Predictive Marker of EGFR-TKIs in NSCLC
Author/study 
(year)
Trial design KRAS status (%) ORR PFS, HR (CI) OS, HR (CI)
No. of patients in 
trial/no. of patients 
with KRAS results
WT Mut WT Mut WT Mut WT Mut
Eberhard et al. 
(2005)16
Paclitaxel/ 
Carboplatin + 
Erlotinib arm
104 (80.6%) 25 (19.4%) 27/104 (26%) 2/25 (8%) TTP: 5.3 mo; (95% 
CI: 4.4–6.1 mo)
TTP 3.4 mo; (95% 
CI, 1.5–6.3 mo)
12.1 mo; (95% CI: 
9.2–15.6 mo)
4.4 mo; (95% CI: 
3.4–12.9 mo)
TRIBUTE 539/129
Giaccone et al. 
(2006)53
All chemotherapy 
naïve patients 
with stage IIIB/IV 
received erotinib
15 (60%) 10 (40%) 4/15 (26.7%) 0/10 (0%) NR >627 days 170 days
ISEL 53/25
p = 0.0059
Hirsch et al. 
(2007)54
All patients with 
advanced NSCLC 
were treated with 
erlotinib
102 (74%) 36 (26%) 19% 7% 3 (2–4) 3(2–4) 11 (6–23) 12(8–15)
204/138
p = 0.237 p = 0.886 p = 0.891
Massarelli et al. 
(2007)55
All patients with 
advanced NSCLC 
were treated 
with erlotinib or 
gefitinib
54 (77.2%) 16 (22.8%) 7/54 (13%) 0/16 (0%) Median TTP 2.9 
mo
Mediian TTP 1.7 mo 9.4 5.0
73/70
p = 0.04 p = 0.0025 p = 0.62
Felipe et al. 
(2008)56
All patients with 
advanced NSCLC 
were treated with 
erlotinib
32(82%) 7 (18%) NR 0/7 (0%) (95% CI: 34–77)a 43 days (95% CI: 
27–118)
111 days (95%  
CI: 86–205)
134 days (95% CI: 
59–220),
83/39
p = 0.8955 p = 0.6454; HR, 1.238
Schneider et al. 
(2008)57
All patients with 
advanced NSCLC 
were treated with 
erlotinib
97(85%) 17(15%) 7/78 (9%) 0/17 (0%) NR 1.56 (0.92–2.65) NR 1.64 (0.97–2.80)
TRUST 393/114
p = 0.094 p = 0.064
Varella-Garcia 
et al. (2009)58
All patients with 
previous surgery 
and recurrent 
disease received 
gefitinib
36 (88%) 5 (12%) 14/26 (54%) 0/4 (0%) TTF 87 days TTF 146 days NR NR
44/41
p = 0.0995 p = 0.0248 p = 0.4156
Zhu et al. 
(2008)17
Patients randomized 
to Erlotinib 
versus placebo in 
advanced NSCLC
176(85%) 30(15%) 10/98 
(10.2%); 
erlotinib 
arm
1/20 (5%); 
erlotinib 
arm
NR NR 0.69 (95% CI: 
0.49–0.97);  
p = 0.03
1.67 (95% CI: 
0.62–4.50); 
 p = 0.31
BR21 731/206
Interaction p = 0.09
Zucali et al. 
(2008)59
All patients received 
gefitinib
34 (69.4%) 15 (30.6%) 3/34 (8.8%) 0/15 (0%) TTP 2.8 mo TTP 4.9 mo 5.0 mo 8.2 mo
51/49
p = 0.543 p = 0.164 p = 0.518
Douillard et al. 
(2009)60,61
Patients with 
advanced NSCLC 
were randomized 
to docetaxel or 
gefitinib
226 (82%) 49 (18%) 9/94 (9.6%); 
gefitinib 
arm
0/20 (0%) 
gefitinib 
arm
HR = 1.23  
(95% CI: 
0.90–1.68); 
 p =0.20; 
median PFS 
(mo):  
gefitinib: 2.6, 
docetaxel: 3.3
HR = 1.16 (95% CI: 
0.56–2.41);  
p = 0.68; median 
PFS (mo): 
gefitinib 1.4, 
docetaxel 1.5
HR = 1.03 (95% CI: 
0.77–1.37); p = 
0.86; G: 7.5 mo; D: 
6.3 mo
HR = 0.81 (95% 
CI: 0.44–1.49); 
p = 0.50; G: 7.8 
mo; D: 4.2 mo
INTEREST 1466/275
Treatment interaction p = 0.51
(Continued)
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TABLE 3. (Continued)
Author/study 
(year)
Trial design KRAS status (%) ORR PFS, HR (CI) OS, HR (CI)
No. of patients in 
trial/no. of patients 
with KRAS results
WT Mut WT Mut WT Mut WT Mut
Jackman  
et al.(2007)62
Chemotherapy-naïve 
patients with 
advanced NSCLC 
≥ 70 with erlotinib
35 (85.4%) 6 (14.6%) 5/35 (14.3%) 0/6 (0%) NR NR NR 15.5 mo (CI: 
4.2–16.8 mo).
82/41
Brugger  
et al.(2011)63
Maintenance erlotinib 
versus placebo 
in patients with 
nonprogressive 
disease after 
first-line 
platinum-doublet 
chemotherapy
403 (82%) 90 (18%) NR NR HR 0.70 (CI: 
0.59–0.87);  
p < 0.001
HR, 0.77; (CI: 
0.50–1.19;  
p = 0.2246
NR NR
SATURN 889/493
Interaction p = 0.95
Sequist et al. 
(2011)64
Patients with 
advanced NSCLC 
randomized to 
erlotinib with 
tivantib or placebo
94 (86%) 15 (14%) NR NR HR 1.01;95%CI: 
0.63–1.60;  
p = 0.977
HR, 0.18; 95% CI: 
0.05–0.70;  
p = 0.013
NR HR: 0.43 (95% 
CI: 0.12–1.50);  
p = 0.17
ArQule 167/109
Interaction p = 0.006
Garassino et al. 
(2012)65
Patients with 
advanced NSCLC 
randomized 
to erlotinib or 
docetaxel as 
second line 
treatment (all 
EGFR wild-type)
168 (76.7%) 51 (23.3%) NR NR HR: O.65 
(0.46–0.9)
HR 0.84 (0.47–1.52) NR NR
TAILOR 222/219
p = 0.237
Metro et al. 
(2012)66
All patients received 
EGFR-TKI
49 (73.2%) 18 (26.8%) NR 3.0 mo 1.6 mo 21 mo 6 mo
67/67 p = 0.04 p = 0.08
Select Studies of KRAS as a Predictive Marker of EGFR-Monoclonal Antibodies in NSCLC
Khambata-Ford 
et al.(2010)67
Patients with 
advanced NSCLC 
randomized to 
taxane/carboplatin 
(T/C) ± (T/C+ 
Cetuximab)
167 (82.7%) 35 (17.3%) Cet + TC 
32.9% 
(28/85)
Cet + TC 
30.8% 
(4/13)
HR: 1.07 (95% CI: 0.77–1.5); p = 0.69 HR: 0.64 
(95% CI: 
0.27–
1.5); 
 p = 0.3
HR: 0.93 
(95% CI: 
0.67–1.3);  
p = 0.68
HR: 0.97 
(95% CI: 
0.45–2.07); 
p = 0.93
BMS099 Trial 676/202
O’Byrne et al. 
(2011)68
Patients with 
advanced NSCLC 
randomized 
to cisplatin/
vinorelbine (C/V) 
± cetuximab (C/
V+ Cet)
320 (81%) 75 (19%) 60/161 
(37.3%)
14/38 
(36.8%)
HR: 0.97 (95% CI: 0.76–1.24); p = 0.80 HR: 0.84 
(95% CI: 
0.50–
1.40);  
p = 0.50
HR: 0.96 
(95% CI: 
0.75–
1.23);  
p = 0.74
HR: 1.00; 
(95% CI: 
0.60–1.66); 
p = 1.00
FLEX 1861/395
Interaction p = 0.38 Interaction p = 0.88
Domine et al. 
(2012)69
Patients treated 
with carboplatin-
docetaxel-
bevacizumab
23 (76.7%) 7 (23.3%) 85.7% 14.3% TTP: 9.38 mo TTP: 
7.46mo
12.6 mo 11.06 mo
p = 0.045 p = 0.033 p = 0.78
aMedian not reported.
Cet, cetuximab; CI, confidence interval; CP, Paclitaxel/carboplatin; D, docetaxel; G, gefitinib; HR, hazard ratio; mo, months; Mut, mutation; NR, not reported; ORR, objective 
response rate; OS, overall survival; PFS, progression-free survival; TTP, time to progression; WT, wild type.
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but in patients with wild-type KRAS tumors, there seemed to 
be benefit with the addition of erlotinib to bevacizumab (HR: 
0.67; CI: 0.49–0.91; p = 0.01).71
In the Sequential Tarceva in unresectable NSCLC 
(SATURN) trial, patients with stage IIIB/IV NSCLC who had 
not experienced disease progression after four cycles of plat-
inum-based therapy were randomized to receive maintenance 
erlotinib or placebo. KRAS mutation was detected in 18%. 
Modest PFS benefit from erlotinib was seen both in patients 
with mutant KRAS tumors and wild-type tumors (interaction 
p = 0.95).63
In the Iressa Non–Small-Cell Lung Cancer Trial 
Evaluating Response Against Taxotere (INTEREST) trial that 
compared second-line gefitinib to docetaxel, 18% had KRAS 
mutations.60 There was no difference in PFS and OS between 
treatment arms according to KRAS status.
There is limited information regarding KRAS mutation 
subtype and response to EGFR-TKIs. One recent investigation 
of KRAS mutation status and response to EGFR-TKI in EGFR 
wild-type advanced NSCLC demonstrated that patients with 
codon 13 KRAS mutations had worse PFS (p = 0.04) and OS 
(p = 0.005) than patients with codon 12 mutations.66 However, 
this study was small, with only 14 and four patients having 
mutations in codons 12 and 13, respectively.
Two meta-analyses have evaluated the association 
between KRAS and EGFR TKI therapy in NSCLC. Linardou 
et al.72 assessed 17 trials involving 1008 patients (165 with 
KRAS mutation). Mutation was significantly associated with 
an absence of response to TKIs (positive likelihood ratio = 
3.52; negative likelihood ratio = 0.84).72 The low pooled sensi-
tivity (0.21; 95% CI: 0.16–0.28) suggests that resistance also 
occurs in a number of wild-type KRAS tumors and that addi-
tional mechanisms of resistance to EGFR-TKIs exist.
Mao et al. included 22 NSCLC studies in their meta-
analysis; 16% of patients (231 of 1470) had KRAS mutations.73 
Response rates were higher for KRAS wild-type compared 
with mutation (26 and 3%, respectively). The pooled relative 
risk for response was 0.29 (95% CI: 0.18–0.47; p < 0.01). 
In the Asian population, the relative risk was 0.22 (95% CI: 
0.07–0.63; p = 0.01) and 0.31 (95% CI: 0.17–0.54; p < 0.01) 
in the white population. Pooled analyses of OS and PFS were 
not performed, as only two studies reported OS and PFS data. 
These two meta-analyses suggest, therefore, that KRAS muta-
tions may be negative predictive biomarkers for response to 
EGFR-TKIs in NSCLC, but a definitive association between 
KRAS status and survival benefit has not been established.
Given the decreased benefit seen with the EGFR mono-
clonal antibodies cetuximab and panitumumab in patients 
with KRAS mutation positive colorectal cancer,51,52 similar 
results were expected in NSCLC. In BMS099, patients with 
advanced NSCLC were randomized to receive taxane/car-
boplatin chemotherapy with or without cetuximab.67 KRAS 
mutations were found in 17% of assessable samples. There 
was no significant association between KRAS status and 
response rate, PFS, or OS. The phase III First-Line ErbituX 
(FLEX) study compared cisplatin/vinorelbine with or without 
cetuximab in EGFR-expressing NSCLC.68 KRAS mutations 
were detected in 19% of assessable samples. The addition of 
cetuximab to chemotherapy did not significantly affect sur-
vival, PFS, or response in patients with KRAS wild-type or 
mutated tumors.
Targeting KRAS
Farnesyl transferase inhibitors
For RAS to be activated, it must be farnesylated (addi-
tion of a nonpolar farnesyl group to the –COOH terminal).74,75 
Farnesyl transferase inhibitors (FTIs) block RAS activation 
through inhibition of farnesyl transferase, ultimately result-
ing in cell growth arrest. Studies of chemotherapy plus FTIs 
in unselected patients with advanced NSCLC have not shown 
improved efficacy.76,77 One trial evaluated the FTI salirasib as 
a single agent in 30 patients with advanced NSCLC harboring 
KRAS mutations; no responses were seen.78
MEK inhibitors
RAS activates the RAS-MEK-ERK pathway, and there 
has been considerable interest in drugs targeting MEK for 
KRAS mutated tumors. Selumetinib, a potent noncompetitive 
inhibitor of MEK-1/2, was shown to be a better inhibitor of 
cell growth in RAS and BRAF mutated cell lines compared 
with those with wild-type genes.79,80 Preclinical work target-
ing MEK-1/2 with selumetinib in melanoma showed in vitro 
and in vivo growth inhibition.81 Although selumetinib alone 
showed only a cytostatic effect, selumetinib with docetaxel 
caused shrinkage of established xenografts. Preclinical stud-
ies in KRAS mutant NSCLC mouse models also have shown 
tumor shrinkage with MEK inhibition.82 Subsequent inves-
tigation in KRAS mutant mice treated with selumetinib and 
docetaxel showed increased apoptosis and decreased pro-
liferation compared with docetaxel alone.79 Chen et al. also 
reported higher response rates in KRAS mutant tumors with 
selumetinib/docetaxel compared with docetaxel alone in 
mouse models.83
In a phase II randomized study, unselected patients 
with advanced NSCLC received either selumetinib100 mg 
orally twice daily or pemetrexed 500 mg/m2 intravenously 
once every 3 weeks.84 There was no significant difference in 
median PFS (67 versus 90 days, respectively; HR: 1.08; 80% 
CI: 0.75–1.54; p = 0.79) or response between the arms.
A phase II, randomized study comparing second-line 
selumetinib/docetaxel (n = 44) to docetaxel (n = 43) in patients 
with KRAS mutant NSCLC85 did not demonstrate a significant 
improvement in OS (p = 0.2069).86 However, there was pro-
longation of PFS (HR: 0.58; 80% CI: 0.42–0.79; p = 0.01), 
and significantly higher response (docetaxel 0%, selumetinib/
docetaxel 37.2%; p < 0.0001).86
Selumetinib is being investigated in the biomarker-inte-
grated targeted therapy study in previously treated patients 
with advanced NSCLC (BATTLE 2).87 In another trial, selu-
metinib is being investigated with or without erlotinib, and 
patients are stratified by KRAS status.88
Other MEK inhibitors, including GSK1120212, are 
being investigated. Preclinical work with GSK1120212 has 
shown cell growth inhibition in RAS mutant cell lines and 
in RAS xenograft models.89 GSK1120212 was evaluated in 
30 heavily pretreated patients with NSCLC (22 with KRAS 
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mutation).90 Two patients achieved partial remission and 10 
had stable disease. When analyzed by KRAS status, median 
PFS was 3.8 months (95% CI: 1.9–5.5) in the subgroup with 
mutations and 2.1 months (95% CI: 1.8–5.2) with wild-type 
KRAS.90 This has led to a randomized trial in patients with 
KRAS mutant NSCLC comparing docetaxel to GSK1120212; 
recruitment is ongoing.91
MET inhibitors
MET tyrosine kinase is involved in cancer cell inva-
sion, proliferation, angiogenesis, and metastasis and can acti-
vate the RAS pathway.92,93 MET amplification is a potential 
mechanism of resistance to EGFR-TKIs in EGFR mutation 
positive NSCLC patients.93 ARQ 197–209 (tivantinib) is a 
non–adenosine triphosphate–competitive small molecule 
MET inhibitor. In the ARQ-197–209 study, previously treated 
patients with NSCLC were randomized to receive erlotinib 
(150 mg/day) plus tivantinib (360 mg twice daily) or erlotinib/
placebo.64 There was modest PFS prolongation with tivantinib 
(HR: 0.81; 95% CI: 0.57–1.16; p = 0.24).64 Of note, in the 
small subset of patients with KRAS mutations (n = 15), there 
was a significant benefit in PFS (HR: 0.18; 95% CI: 0.05–
0.70; p < 0.01, interaction p = 0.006) and OS (HR: 0.43; 95% 
CI: 0.12–1.50; p = 0.17). In the large 998 patient confirma-
tory trial (MET inhibitor ARQ-197/erlotinib versus erlotinib/
placebo in NSCLC [MARQUEE]), patients were stratified 
by EGFR and KRAS mutation status.94 However, the trial was 
halted by the Data Monitoring Committee following interim 
analysis determined that the primary endpoint of OS was not 
expected to be met, although  a significant PFS in the intent 
to treat population was seen.94a Subset analysis on the KRAS 
mutation-positive  patients is awaited. In another ongoing trial 
limited to patients with KRAS mutant tumors, randomization 
is to tivantinib/erlotinib or physician’s choice chemotherapy 
(gemcitabine, docetaxel, or pemetrexed).95
Other agents
mTOR is a serine/threonine kinase that regulates cell 
growth, proliferation, survival, and protein synthesis. It is a 
downstream mediator in the phosphatidylinositol 3-kinase/Akt 
signaling pathway.96 Ridaforolimus, a small-molecule mTOR 
inhibitor was investigated in a randomized discontinuation 
study in patients with advanced KRAS mutant NSCLC who 
had failed previous chemotherapy.97 Patients with stable dis-
ease after 8 weeks of ridaforolimus were randomized to rida-
forolimus or placebo. Median PFS was significantly longer 
with ridaforolimus (4 versus 2 months; HR: 0.36; p = 0.013). 
OS from randomization was 18 months in the ridaforolimus 
arm and 5 months in the placebo group (HR: 0.46; p = 0.09).97
Heat shock proteins (HSP) are a class of functionally 
related proteins that are active under conditions of cellular stress, 
that function as molecular chaperones in the post-translational 
folding and synthesis of proteins.98 Preclinical work with KRAS 
mutated NSCLC cell lines and murine models have demonstrated 
high sensitivity to HSP90 inhibitors.99 Ganetespib, a second-
generation small molecule inhibitor of HSP90, displayed potent 
anticancer activity across a diverse spectrum of KRAS mutant 
NSCLC cell lines.100 Treatment with a combination of gane-
tespib with alkylating agents, antimitotics, and topoisomerase 
inhibitors resulted in increased cell death compared with gane-
tespib alone. Similarly, combinations of ganetespib with targeted 
agents (MEK and PI3K/mTOR inhibitors) resulted in slower 
tumor growth than ganetespib alone. This has prompted further 
trials investigating ganetespib. In the phase II study involving 73 
patients, ganetespib was administered as monotherapy in patients 
with advanced NSCLC.101 Among 14 assessable patients with 
 wild-type EGFR and KRAS mutation, one patient achieved par-
tial response and seven patients had stable disease (≥16 weeks). 
In addition, a phase IIB/III study of docetaxel ± ganetespib in 
subjects with stage IIIb or IV NSCLC is ongoing.102
Sorafenib, a multikinase inhibitor, was investigated in 
a phase I trial of 10 previously treated patients with KRAS 
mutated tumors; the median PFS was 3 months (95% CI: 2.2–
2.8 months).103 However, a subsequent phase II trial of 57 pre-
viously treated patients with KRAS mutated tumors reported 
less optimistic results with median PFS and OS of only 2.3 and 
5.3 months, respectively.104 In the phase II BATTLE-1 trial,105 
the disease control rate for patients treated with sorafenib was 
61% in patients with KRAS mutations versus 56% in KRAS 
wild type. In another phase II study of sorafenib in 37 pre-
viously treated patients with NSCLC, 11 patients (32%) had 
KRAS mutation. The disease control rate observed in these 
patients was 60 versus 71% in those with KRAS wild-type 
tumors (p = 0.69).106
DISCUSSION AND CONCLUSIONS
Despite 20 years of research, the prognostic role of KRAS 
continues to be debated with inconsistent results reported 
among trials.39 Even in pooled analyses and meta-analyses, the 
results have been variable. Mascaux et al.39 reported significant 
heterogeneity among the studies (p = 0.03) in their meta-anal-
ysis, and although the test for heterogeneity was not signifi-
cant in the LACE-Bio pooled analysis (p = 0.59), the actual 
results varied widely with HRs ranging from 1.03 to 1.42.40 
Furthermore, these two studies demonstrated different effects 
in specific histological subtypes. Mascaux et al. found KRAS to 
be a negative prognostic marker in adenocarcinoma but not in 
squamous NSCLC.39 In contrast, LACE-Bio reported no prog-
nostic effect in adenocarcinoma (HR: 1.03), with a significant 
effect only in the very small nonsquamous nonadenocarcinoma 
subgroup.40 It is difficult to explain these discrepant results 
based on differences in patient characteristics or other baseline 
demographics. In particular, the lack of any trend in adeno-
carcinoma in the LACE-Bio study is unexpected because this 
is the histological subtype most associated with KRAS muta-
tion, and the subtype that should have had the statistical power 
to show a significant difference. These results emphasize the 
potential difficulty of identifying true prognostic markers for 
NSCLC. KRAS is mutated in approximately 20% of NSCLCs, 
yet even with 1700 patients studied and 300 mutations identi-
fied, LACE-Bio did not have the power to demonstrate signifi-
cant differences. This demonstrates the difficulty that will be 
seen in future attempts to determine the prognostic effect of 
rare mutations that occur in 5% or lesser tumors.
The initial studies reporting KRAS as a potential predic-
tive marker of chemotherapy resistance were small and fre-
quently did not have untreated control arms. The LACE-Bio 
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pooled analysis had the greatest potential to detect a significant 
predictive effect for KRAS because all studies had untreated 
control arms and the adjuvant treatment was platinum-based 
in all trials. On first glance, it seems that only patients with 
wild-type KRAS tumors derived benefit (HR: 0.89) with 
no benefit seen in those with mutated tumors (HR: 1.02).40 
However, from a statistical point of view, no interaction could 
be demonstrated (interaction p = 0.50). Furthermore, in the 
largest subgroup of adenocarcinoma, the benefit from che-
motherapy was almost identical in patients with mutated and 
wild-type tumors (wild-type HR: 0.88; mutant HR: 0.92). In 
addition, there was considerable variability among the trials 
with more benefit seen in KRAS mutant tumors in ANITA, less 
benefit in JBR.10 and Cancer and Leukemia Group B-9633 
and no difference in IALT. Based on these studies, there is no 
compelling evidence that KRAS status can be used as a selec-
tion tool for chemotherapy at this time.
To date, EGFR mutation status is the strongest predic-
tive marker for response to EGFR-TKIs.10,107,111 EGFR muta-
tion and KRAS are almost mutually exclusive, and some but 
not all studies have suggested that KRAS mutation confers 
some degree of resistance to EGFR TKIs in patients with 
wild-type EGFR. Although the majority of studies suggest no 
statistically significant effect of KRAS in differential survival 
benefit from EGFR TKIs in NSCLC, two meta-analayses sug-
gest that KRAS may be a negative predictive biomarker for 
response (tumor shrinkage) to EGFR-TKIs in NSCLC.72,73 At 
present, the evidence is not strong enough for KRAS status to 
be used to affect EGFR TKI treatment even in those patients 
with wild-type KRAS. With the increasing use of molecular 
profiling of tumors to assess for multiple mutations, it is likely 
that further information will result in a clearer understanding 
of the interaction between mutations and their effect on sur-
vival and treatment. This may result in the division of NSCLC 
into molecular subset classifications.
Although KRAS mutations in advanced colorectal can-
cer predict a lack of benefit from EGFR monoclonal antibody 
therapy,51,52 this is not the case in NSCLC with two studies 
showing that KRAS was not predictive of response or survival 
outcome when cetuximab was added to chemotherapy.67,68 
This discrepancy may result from the different mutations that 
are seen in the two diseases. In NSCLC, the smoking-related 
G>T or G>C transversion is most commonly seen, whereas in 
colorectal cancer, G>A transitions are more common.15,19–21,112 
Never smokers with NSCLC are more likely to have transi-
tion mutations (G>A) as well.15 Downstream signaling result-
ing from the different KRAS mutations may be different in 
NSCLC and colorectal cancer, and even within a specific 
cancer. Signaling studies on NSCLC cell lines have demon-
strated that activation of different downstream signaling path-
ways occurs as a result of different amino acid substitutions in 
mutant KRAS tumors.108
Additional factors such as disruption of microRNA 
regulation by single-nucleotide polymorphisms may affect 
the function of KRAS. In turn, this may play a role in deter-
mining response to therapies. Recently, a variant in the KRAS 
oncogene in the 3′ untranslated region has been investigated 
in ovarian cancer where in a Cox regression model, patients 
with the KRAS variant had significantly shorter survival 
compared with those without (HR: 1.67; 95% CI: 1.09–2.57; 
p = 0.019).109 One possible explanation for this was the finding 
that patients with the KRAS variant were more likely to have 
platinum resistance as evidenced by both a worse response 
to neoadjuvant platinum-based chemotherapy and increased 
platinum resistance in the adjuvant setting.109 Furthermore, 
this same variant has been shown to be associated with a 
higher risk of NSCLC in moderate smokers.110 Further inves-
tigation in NSCLC assessing the role this pharmacogenomic 
variant has on treatment effect is warranted.
To date, trials of therapeutic inhibitors of RAS have 
been disappointing. The failure of these drugs may result 
from up-regulation of alternative signaling pathways after 
the inhibition of RAS or the use of alternative cellular path-
ways for post-translational modification of KRAS.17 Activated 
RAS relays EGFR signaling to multiple downstream effectors 
including Raf-MEK-ERK and PI3K cascade and mutations in 
RAS lead to its constitutive activation of downstream effec-
tors.26 Recently, agents targeting the downstream effectors of 
KRAS (PI3K-AKT-mTOR and RAS-RAF-MEK) have shown 
some promise, and confirmatory randomized studies with 
these agents are ongoing.87,88,91,94,95 However, inhibition of one 
pathway may lead to up-regulation of a related network and 
may, therefore, not have the desired effect. This suggests that 
combination therapy may be necessary, but as has been the 
case so frequently in NSCLC, toxicity may limit the useful-
ness of such combinations. Greater knowledge of the genome 
and identification of mutations in key genes that have regula-
tory roles in cellular proliferation may lead to individually tar-
geted therapeutic approaches in NSCLC. However, targeting 
KRAS remains experimental, and this oncogene cannot, at this 
time, be recommended routinely for selection (or exclusion) 
of patients for therapy.
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